Sign In
Buy OPY
$106.64
-4.06 (-3.67%)
At Close: Jul 31, 2026
Intercept Pharmaceuticals (NASDAQ:ICPT) Lowered to Hold at Canaccord Genuity
01:36pm, Monday, 29'th Jun 2020
Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at Canaccord Genuity from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Briefing.
Analyst Explains Why They Downgraded Their Rating on Intercept Pharma (ICPT) - Markets
01:29pm, Monday, 29'th Jun 2020
In a report released today, Jay Olson from Oppenheimer downgraded Intercept Pharma (ICPT – Research Report) to Hold, with a
Analysts Anticipate 8×8, Inc. (NYSE:EGHT) Will Post Earnings of -$0.13 Per Share
01:28pm, Monday, 29'th Jun 2020
Analysts expect 8×8, Inc. (NYSE:EGHT) to announce ($0.13) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for 8X8’s earning
-$0.25 EPS Expected for Tactile Systems Technology Inc (NASDAQ:TCMD) This Quarter
12:34pm, Monday, 29'th Jun 2020
Equities analysts expect Tactile Systems Technology Inc (NASDAQ:TCMD) to announce ($0.25) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Tactile
Weekly Research Analysts’ Ratings Changes for Paypal (PYPL)
12:22pm, Monday, 29'th Jun 2020
Several brokerages have updated their recommendations and price targets on shares of Paypal (NASDAQ: PYPL) in the last few weeks: 6/26/2020 – Paypal had its price target raised by analysts at Bank o
Recent Investment Analysts’ Ratings Updates for Corbus Pharmaceuticals (CRBP)
12:22pm, Monday, 29'th Jun 2020
Corbus Pharmaceuticals (NASDAQ: CRBP) recently received a number of ratings updates from brokerages and research firms: 6/26/2020 – Corbus Pharmaceuticals was upgraded by analysts at BidaskClub from
IQIYI (IQ) – Research Analysts’ Weekly Ratings Changes
12:22pm, Monday, 29'th Jun 2020
A number of firms have modified their ratings and price targets on shares of IQIYI (NASDAQ: IQ) recently: 6/25/2020 – IQIYI was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperf
$57.04 Million in Sales Expected for Limelight Networks, Inc. (NASDAQ:LLNW) This Quarter
12:20pm, Monday, 29'th Jun 2020
Equities research analysts predict that Limelight Networks, Inc. (NASDAQ:LLNW) will post sales of $57.04 million for the current quarter, Zacks Investment Research reports. Five analysts have made est
Leerink Partners Remains a Hold on Intersect ENT (XENT) - Markets
11:56am, Monday, 29'th Jun 2020
In a report released today, Richard Newitter from Leerink Partners maintained a Hold rating on Intersect ENT (XENT – Research
$22.70 Million in Sales Expected for Crispr Therapeutics AG (NASDAQ:CRSP) This Quarter
11:38am, Monday, 29'th Jun 2020
Wall Street analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will report $22.70 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Cri
Global Payments (NYSE:GPN) PT Raised to $202.00
11:18am, Monday, 29'th Jun 2020
Global Payments (NYSE:GPN) had its price objective hoisted by equities researchers at Oppenheimer from $190.00 to $202.00 in a research note issued on Monday, The Fly reports. The brokerage currently
A Cheap, Race-Neutral Way to Close the Racial Wealth Gap
10:00am, Monday, 29'th Jun 2020
It’s time to try baby bonds.
Fortinet’s (FTNT) “Buy” Rating Reiterated at Oppenheimer
08:54am, Monday, 29'th Jun 2020
Fortinet (NASDAQ:FTNT)‘s stock had its “buy” rating restated by research analysts at Oppenheimer in a research report issued on Monday, AnalystRatings.com reports. They currently have a $160.00
New Mexico Educational Retirement Board Acquires 6,000 Shares of XPO Logistics Inc (NYSE:XPO)
08:50am, Monday, 29'th Jun 2020
New Mexico Educational Retirement Board raised its holdings in shares of XPO Logistics Inc (NYSE:XPO) by 37.5% during the first quarter, according to its most recent filing with the Securities and Exc
SVB Leerink Trims Intersect ENT (NASDAQ:XENT) Target Price to $14.00
08:26am, Monday, 29'th Jun 2020
Intersect ENT (NASDAQ:XENT) had its target price lowered by investment analysts at SVB Leerink from $15.00 to $14.00 in a research note issued to investors on Monday, BenzingaRatingsTable reports. The
